Cinacalcet: The first calcimimetic approved for secondary hyperparathyroidism

Formulary

Volumn 39, Issue 10, 2004, Pages 482-489

  Dang, Devra K ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b Burgdorf Fleet Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; CYTOCHROME P450; DOXERCALCIFEROL; FLECAINIDE; KETOCONAZOLE; PANTOPRAZOLE; PARACALCITRIOL; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; SEVELAMER; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

BONE DISEASE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIALYSIS; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GRAND MAL SEIZURE; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOCALCEMIA; NAUSEA; PARATHYROID CARCINOMA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; REVIEW; SECONDARY HYPERPARATHYROIDISM; TESTOSTERONE BLOOD LEVEL; THROMBOSIS; TONIC CLONIC SEIZURE; VASCULAR ACCESS; VOMITING;

EID: 6344285623     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Fukagawa M, Kazama JJ, Kurokawa K. Renal osteodystrophy and secondary hyperparathyroidism. Nephrol Dial Transplant. 2002;17(suppl 10):2-5.
2. Goodman WG. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial. 2004;17:209-216.
3. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol. 2002;39:695-701.
4. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31:607-617.
5. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131-2138.
6. Clark OH. How should patients with primary hyperparathyroidism be treated? J Clin Endocrinol Metab. 2003;88:3011-3014.
7. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney. Am J Kidney Dis. 2003;42(suppl 3):S1-S201.
8. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:5644-5649.
9. Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol. 2002;13:1017-1024.
10. Sensipar [package insert]. Thousand Oaks, Calif: Amgen; 2004.
11. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003;63:248-254.
12. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003;14:575-583.
13. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516-1525.
14. Lindberg JS, Culleton B, Wong G, et al. Phase 3 experience with cinacalcet HCl in hemodialysis and peritoneal dialysis patients with secondary HPT [abstract]. J Am Soc Nephrol. 2003;14:463A. Abstract SA-PO752.
15. Owda AK, Alam MG, Kumar J. Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients [author reply]. N Engl J Med. 2004;351:188-189.
16. Quarles LD, Zeig S, Spiegel DM, et al. Cinacalcet HCl controls secondary hyperparathyroidism in dialysis patients regardless of disease severity [abstract]. J Am Soc Nephrol. 2003;14:463A. Abstract SA-PO751.
17. Moe SM, Sprague SM, Cunningham J, et al. Long-term treatment of secondary hyperparathyroidism (HPT) with the calcimimetic cinacalcet HCl [abstract]. J Am Soc Nephrol. 2003;14:463A. Abstract SA-PO753.
18. Urena Torres P. Clinical experience with cinacalcet HCl. Nephrol Dial Transplant. 2004;19(suppl 5): V27-V33.
19. Padhi D, Harris R, Salfi M, et al. Cinacalcet HCl absorption in study subjects is not affected by coadministration of medications commonly prescribed to chronic kidney disease (CKD) patients (pantoprazole, sevelamer HCl, and calcium carbonate) [abstract]. J Am Soc Nephrol. 2003;14:461A. Abstract SA-PO744.
20. Chertow GM, Burke SK, Raggi P, and the Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245-252.
21. Amin N. The impact of improved phosphorus control: Use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant. 2002;17:340-345.
22. Drug Topics Red Book. Montvale, NJ: Thomson PDR; 2004. F